Alkermes (NASDAQ:ALKS) Price Target Raised to $44.00 at Wells Fargo & Company

Alkermes (NASDAQ:ALKS) had its price target hoisted by analysts at Wells Fargo & Company from $43.00 to $44.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would suggest a potential upside of 23.92% from the company’s previous close.

Several other research analysts have also issued reports on ALKS. Truist Financial upgraded shares of Alkermes to a “strong-buy” rating in a research report on Wednesday, March 25th. Wolfe Research started coverage on shares of Alkermes in a research report on Monday, February 23rd. They issued an “outperform” rating and a $45.00 price target on the stock. Zacks Research upgraded shares of Alkermes from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings upgraded shares of Alkermes from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, April 27th. Finally, Wall Street Zen lowered shares of Alkermes from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alkermes presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.79.

Alkermes Trading Down 2.0%

NASDAQ:ALKS traded down $0.74 during midday trading on Wednesday, hitting $35.51. 400,006 shares of the stock were exchanged, compared to its average volume of 2,222,182. Alkermes has a one year low of $25.17 and a one year high of $36.60. The company has a market capitalization of $5.90 billion, a price-to-earnings ratio of 24.83 and a beta of 0.31. The business has a 50-day moving average price of $31.53 and a two-hundred day moving average price of $30.98.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Saturday, February 14th. The company reported $0.29 earnings per share (EPS) for the quarter. The firm had revenue of $384.55 million for the quarter. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. Sell-side analysts forecast that Alkermes will post -0.69 EPS for the current fiscal year.

Insider Buying and Selling at Alkermes

In other Alkermes news, SVP Christian Todd Nichols sold 6,000 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $30.00, for a total transaction of $180,000.00. Following the sale, the senior vice president directly owned 109,769 shares of the company’s stock, valued at $3,293,070. The trade was a 5.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $33.40, for a total transaction of $300,600.00. Following the sale, the executive vice president directly owned 81,389 shares in the company, valued at approximately $2,718,392.60. This trade represents a 9.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 39,102 shares of company stock valued at $1,265,090 in the last three months. 4.59% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alkermes

Several institutional investors and hedge funds have recently modified their holdings of ALKS. Assetmark Inc. grew its holdings in shares of Alkermes by 933.8% during the 3rd quarter. Assetmark Inc. now owns 827 shares of the company’s stock valued at $25,000 after acquiring an additional 747 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new position in shares of Alkermes during the 4th quarter valued at $28,000. Johnson Financial Group Inc. purchased a new position in shares of Alkermes during the 3rd quarter valued at $31,000. UMB Bank n.a. grew its holdings in shares of Alkermes by 57.6% during the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after acquiring an additional 446 shares in the last quarter. Finally, Salomon & Ludwin LLC grew its holdings in shares of Alkermes by 115.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock valued at $35,000 after acquiring an additional 667 shares in the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

More Alkermes News

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Q1 results beat estimates: Alkermes reported ($0.43) EPS vs. consensus ($0.57) and revenue of $392.9M vs. $363.3M, driven by product sales growth. Strong top‑line and an EPS beat helped lift sentiment. Q1 Press Release
• Positive Sentiment: Analyst upgrade / price‑target raise: Needham raised its price target to $50 and reiterated a Buy, implying meaningful upside from current levels — a direct positive catalyst for investor demand. Needham / TickerReport
• Positive Sentiment: Earnings‑call tone and product momentum: Management highlighted LUMRYZ momentum and an upbeat call narrative, which supports the revenue beat and longer‑run commercial expectations. Earnings Call Summary
• Neutral Sentiment: Research / thematic note: A Seeking Alpha piece highlights Alkermes’ potential sleep‑medicine platform embedded inside its CNS franchise — interesting strategic upside but speculative and longer horizon. Seeking Alpha
• Neutral Sentiment: Insider transaction: EVP David Gaffin sold 2,034 shares under a pre‑arranged Rule 10b5‑1 plan — disclosed sale but not an unexpected governance red flag given the plan. SEC Form 4
• Negative Sentiment: Guidance disappointed: Fiscal‑2026 EPS guidance of roughly -$0.521 to -$0.405 and revenue guidance toward the lower end of $1.7–1.8B came in below consensus estimates, creating near‑term uncertainty and capping valuation multiple expansion. Guidance / Press Release

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.